Table 3.
Pathologic outcomes at radical prostatectomy.
| Current Analysis Cohort (n=70) | Original Trial Cohorts | |||||||
|---|---|---|---|---|---|---|---|---|
| TAPS (n=32) | Neo-Abi (n=56) | Neo-Enza (n=48) | ||||||
| N | % | N | % | N | % | N | % | |
| Pathologic T stage | ||||||||
| pT0 | 4 | 5.7 | 2 | 6.3 | 4 | 7.1 | 1 | 2.1 |
| pT2 | 27 | 38.6 | 21 | 65.6 | 22 | 39.3 | 15 | 31.3 |
| pT3 | 39 | 55.7 | 9 | 28.1 | 30 | 53.6 | 32 | 66.7 |
| Pathologic T Down-Stage* | ||||||||
| Yes | 10 | 14.3 | - | - | - | - | - | - |
| No | 57 | 81.4 | - | - | - | - | - | - |
| Unknown | 3 | 4.3 | - | - | - | - | - | - |
| Pathologic N Stage | ||||||||
| N0 | 61 | 87.1 | - | - | 46 | 82.1 | 41 | 85.4 |
| N1 | 8 | 11.4 | - | - | 10 | 17.9 | 7 | 14.6 |
| Unknown | 1 | 1.4 | - | - | 0 | 0 | 0 | 0 |
| Positive Margin | ||||||||
| Yes | 9 | 12.9 | - | - | 8 | 14.3 | 9 | 18.8 |
| No | 61 | 87.1 | - | - | 48 | 85.7 | 39 | 81.3 |
| Seminal Vesicle Involvement | ||||||||
| Yes | 28 | 40.0 | 5 | 15.6 | 17 | 30.4 | 16 | 33.3 |
| No | 42 | 60.0 | 27 | 84.4 | 39 | 69.6 | 32 | 66.7 |
| Largest Cross Section Dimension | ||||||||
| ≤0.5cm | 11 | 15.7 | - | - | - | - | - | - |
| >0.5cm | 55 | 78.6 | - | - | - | - | - | - |
| Unknown | 4 | 5.7 | - | - | - | - | - | - |
| Pathologic Complete Response | ||||||||
| Yes | 4 | 5.7 | 2 | 6.3 | 4 | 7.1 | 1 | 2.1 |
| No | 66 | 94.3 | 30 | 93.7 | 52 | 92.9 | 47 | 97.9 |
*
Downstaging of clinical T stage as defined by AJCC staging system at diagnosis to pathologic T stage at radical prostatectomy. Improved from T1c to pT0 (N=2), T2a to pT0 (N=1), T2b to pT2a (N=1), T2c to pT0 (N=1), T3 to pT2 (N=1), T3a to pT2a (N=2), T3a to pT2c (N=1), T3b to pT3a (N=1).
- denotes not available.